A state-of-the-art review of stratified medicine in cancer: towards a future precision medicine strategy in cancer

G. Middleton, H. Robbins, F. Andre, C. Swanton

    Research output: Contribution to journalReview articlepeer-review

    32 Citations (Scopus)

    Abstract

    Background: Building on the success of targeted therapy in certain well-defined cancer genotypes, three platform studies—NCI-MATCH, LUNG-MAP and The National Lung Matrix Trial (NLMT)—have attempted to discover new genotype-matched therapies for people with cancer. Patients and methods: We review the outputs from these platform studies. This review led us to propose a series of recommendations and considerations that we hope will inform future precision medicine programmes in cancer. Results: The three studies collectively screened over 13 000 patients. Across 37 genotype-matched cohorts, there have been 66/875 responders, with an overall response rate of 7.5%. Targeting copy number gain yielded 5/199 responses across nine biomarker–drug matched cohorts, with a response rate of 2.5%. Conclusions: The majority of these studies used single-agent targeted therapies. Whilst preclinical data can suggest rational combination treatment to reverse adaptive resistance or block parallel activated pathways, there is an essential need for accurate modelling of the toxicity–activity trade-off of combinations. Agent selection is often suboptimal; dose expansion should only be carried out with agents with clear clinical proof of mechanism and high target selectivity. Targeting copy number change has been disappointing; it is crucial to define the drivers on shared amplicons that include the targeted aberration. Maximising outcomes with currently available targeted therapies requires moving towards a more contextualised stratified medicine acknowledging the criticality of the genomic, transcriptional and immunological context on which the targeted aberration is inscribed. Genomic complexity and instability is likely to be a leading cause of targeted therapy failure in genomically complex cancers. Preclinical models must be developed that more accurately capture the genomic complexity of human disease. The degree of attrition of studies carried out after standard-of-care therapy suggests that serious efforts be made to develop a suite of precision medicine studies in the minimal residual disease setting.

    Original languageEnglish
    Pages (from-to)143-157
    Number of pages15
    JournalAnnals of Oncology
    Volume33
    Issue number2
    DOIs
    Publication statusPublished - 1 Feb 2022

    Keywords

    • genotype matching
    • platform trials
    • precision medicine
    • targeted therapy

    Cite this